With such remarkable outcomes across two Phase 3 studies, lenacapavir has demonstrated the potential to transform the prevention of HIV and help to end the epidemic.
The trials were halted early after determining they had met key efficacy endpoints, indicating lenacapavir's effectiveness far exceeded expectations against daily Truvada.
In the United States, the stubbornly high rate of HIV diagnoses...demands novel approaches to help people prevent HIV acquisition.
Lenacapavir showed a reported 96 percent relative risk reduction versus background HIV, proving itself as a significant advancement in HIV prevention.
[
Collection
]
[
|
...
]